Evidence map›Paper›PMID 34166680›Full record

ArticleToxicology and applied pharmacology2021

The role of PD-1/PD-L1 checkpoint in arsenic lung tumorigenesis.

Wenhua Xu, Jiajun Cui, Linqing Wu, Caigu He, Gang Chen

Open access · greenAbstract read
In one paragraph

Article in Toxicology and applied pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Wenhua XuDepartment Pharmacology & Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY 40536, USA; Department of Neurology, the First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui 230001, China.
Jiajun CuiDepartment Pharmacology & Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY 40536, USA; Department of Biochemistry, College of Medicine, Yichun University, Yichun, Jiangxi 336000, China.
Linqing WuDepartment Pharmacology & Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY 40536, USA; Department of Immunology, School of Basic Medical Sciences, Fujian Medical University, FuZhou, Fujian 350003, China.
Caigu HeDepartment Pharmacology & Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY 40536, USA; Department of Histology and Embryology, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 361000, China.
Gang ChenDepartment Pharmacology & Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY 40536, USA. Electronic address: gangchen6@uky.edu.
University of Kentucky · USFujian University of Traditional Chinese Medicine · CNUniversity of Science and Technology of China · CN

Funding

University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI KATHLEEN L. O'CONNOR · 2013 to 2026
$38.3M
Microenvironment and Arsenic Lung TumorigenesisR01ES026657 · NIEHS · UNIVERSITY OF KENTUCKY · PI CHEN, GANG · 2017 to 2022
$1.7M
NCI NIH HHS P30 CA177558NIEHS NIH HHS R01 ES026657
6 · The paper itself

Abstract

Chronic exposure to environmental arsenic promotes lung cancer. Emerging evidence indicates that compromised host immunity, particularly T cell anti-tumor immunity, may play a critical role in cancer development. However, there is a knowledge gap in terms of the effects of arsenic exposure on T cell anti-tumor immunity and how that may contribute to arsenic lung carcinogenicity. Immunosuppression has been known as a risk factor for many types of cancer, including lung cancer. The development of cancer indicates the success of immunosuppression and escape of cancer cells from host anti-tumor immunity in which T cells are the major component. The anti-tumor immunity is mainly executed by CD8 cytotoxic T cells through their anti-tumor effector function, which can be regulated by immune checkpoint pathways. Some inhibitory receptors on the T cell membrane and their ligands form these pathways, among which programmed death-1 (PD-1), a T cell inhibitory receptor, and its ligand, programmed death-ligand 1 (PD-L1), are best characterized. A/J mice are naturally sensitive to pulmonary carcinogens, prone to develop spontaneous lung tumors later in life and have been frequently used as an animal model for lung tumorigenesis research. Chronic arsenic administration through drinking water has been shown to enhance tumor formation in the lungs of A/J mice. In the current study, using this mouse model we want to determine whether PD-1/PD-L1 plays a role in arsenic-enhanced lung tumorigenesis. The results showed that prolonged arsenic exposure up-regulated PD-1/PD-L1, increased regulatory T cells (Tregs), decreased CD8/Treg ratio, inhibited T cell antitumor function in the lungs and enhanced lung tumor formation, while inhibition of PD-1/PD-L1 restored CD8/Treg ratio and T cell anti-tumor effector function, and mitigated arsenic-enhanced lung tumorigenesis. In addition, inhibition of PD-1/PD-L1 could be a potential preventive strategy to mitigate the tumorigenic action of chronic arsenic exposure.

Indexed as

AnimalsArsenicB7-H1 AntigenCarcinogenesisCD8-Positive T-LymphocytesFemaleImmunoglobulin GLung NeoplasmsMaleMiceProgrammed Cell Death 1 ReceptorT-Lymphocytes, RegulatoryArsenicB7-H1 AntigenCd274 protein, mouseImmunoglobulin GPdcd1 protein, mouseProgrammed Cell Death 1 ReceptorArsenicLungPD-1PD-L1T cellTumor

Identifiers

PMID34166680
PMCPMC8338898
OpenAlexW3175463225

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.